Association of Hypomagnesemia and Liver Injury, Role of Gut-Barrier Dysfunction and Inflammation: Efficacy of Abstinence, and 2-Week Medical Management in Alcohol Use Disorder Patients.
alcohol use disorder
alcoholic liver disease
early-stage ALD
heavy drinking
hypomagnesemia
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 Sep 2022
26 Sep 2022
Historique:
received:
16
05
2022
revised:
14
09
2022
accepted:
16
09
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
(1) We investigated the involvement of serum magnesium level in early alcoholic liver disease (ALD), gut barrier dysfunction, and inflammation in alcohol use disorder (AUD) patients; and lastly, the efficacy of 2-week abstinence and medical management to alleviate hypomagnesemia. (2) Forty-eight heavy drinking AUD patients (34 males (M)/14 females (F)) participated in this study. Patients were grouped by serum alanine aminotransferase (ALT) level (a marker of liver injury) as group 1 (Group 1 (Gr.1); ALT ≤ 40 U/L, 7M/8F, without any indication of early-stage ALD) and group 2 (Group 2 (Gr.2); ALT > 40 U/L, 27M/6F or early-stage ALD). These patients were sub-divided within each group into patients with normal magnesium (0.85 and more mmol/L) and deficient magnesium (less than 0.85 mmol/L) levels. All participants were assessed at baseline (BL) and received standard medical management for 2 weeks with reassessment at the treatment end (2w). (3) Female participants of this study showed a significantly lower baseline level of magnesium than their male counterparts. Gr.2 patients showed a greater propensity in the necrotic type of liver cell death, who reported higher chronic and recent heavy drinking. Magnesium level improved to the normal range in Gr.2 post-treatment, especially in the hypomagnesemia sub-group (0.77 ± 0.06 mmol/L (BL) vs. 0.85 ± 0.05 mmol/L (2w), p = 0.02). In Gr.2, both apoptotic (K18M30) and necrotic (K18M65) responses were significantly and independently associated with inflammasome activity comprising of LBP (Lipopolysaccharide binding-protein) and TNFα (Tumor necrosis factor -α), along with serum magnesium. (4) In AUD patients with liver injury, 2-week medical management seems to improve magnesium to a normal level. This group exhibited inflammatory activity (LBP and TNFα) contributing to clinically significant hypomagnesemia. In this group, the level of magnesium, along with the unique inflammatory activity, seems to significantly predict apoptotic and necrotic types of hepatocyte death.
Identifiants
pubmed: 36232646
pii: ijms231911332
doi: 10.3390/ijms231911332
pmc: PMC9569745
pii:
doi:
Substances chimiques
Inflammasomes
0
Lipopolysaccharides
0
Tumor Necrosis Factor-alpha
0
Alanine Transaminase
EC 2.6.1.2
Magnesium
I38ZP9992A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAAA NIH HHS
ID : K23AA029198-02 (VV)
Pays : United States
Références
J Hepatol. 2019 Feb;70(2):273-283
pubmed: 30658728
Subst Abuse Treat Prev Policy. 2008 Jan 25;3:1
pubmed: 18218147
Sci Rep. 2017 Dec 20;7(1):17913
pubmed: 29263344
Magnes Res. 1998 Jun;11(2):85-9
pubmed: 9675752
Alcohol Alcohol. 2020 Mar 19;55(2):164-170
pubmed: 32047901
Cells. 2020 Feb 25;9(3):
pubmed: 32106390
Tohoku J Exp Med. 2011;224(3):215-9
pubmed: 21701127
Open Heart. 2018 Jan 13;5(1):e000668
pubmed: 29387426
Hum Exp Toxicol. 2011 Nov;30(11):1811-27
pubmed: 21474619
Arch Gen Psychiatry. 2010 Oct;67(10):1069-77
pubmed: 20921123
Alcohol Res. 2017;38(2):147-161
pubmed: 28988570
Ann Transl Med. 2019 Oct;7(20):578
pubmed: 31807559
Int J Mol Med. 2016 Jul;38(1):275-82
pubmed: 27220460
Alcohol Clin Exp Res. 2003 Oct;27(10):1661-6
pubmed: 14574238
Gene Expr. 2017 Nov 27;17(4):301-312
pubmed: 28770701
Curr Opin Nephrol Hypertens. 2016 Jul;25(4):301-7
pubmed: 27219040
Int J Mol Sci. 2022 May 23;23(10):
pubmed: 35628661
J Stud Alcohol. 1982 Nov;43(11):1157-70
pubmed: 7182675
Biomedicines. 2020 Dec 24;9(1):
pubmed: 33374263
Curr Drug Abuse Rev. 2017;9(2):87-92
pubmed: 28124600
Int Rev Neurobiol. 2014;118:359-80
pubmed: 25175869
Clin Gastroenterol Hepatol. 2020 Aug;18(9):2046-2054
pubmed: 31811953
Am J Physiol Gastrointest Liver Physiol. 2003 Jan;284(1):G57-67
pubmed: 12488234
Drug Chem Toxicol. 2017 Jan;40(1):47-56
pubmed: 27151930
Alcohol. 2022 Aug;102:51-57
pubmed: 35452750
Semin Liver Dis. 1991 Nov;11(4):321-39
pubmed: 1763338
Magnes Trace Elem. 1991-1992;10(2-4):263-8
pubmed: 1844558
Clin Gastroenterol Hepatol. 2019 Oct;17(11):2320-2329.e12
pubmed: 30708110
Quad Sclavo Diagn. 1987 Mar;23(1):12-7
pubmed: 3441590
J Trace Elem Med Biol. 1995 Dec;9(4):210-4
pubmed: 8808192
United European Gastroenterol J. 2018 Feb;6(1):97-103
pubmed: 29435319
Dis Mon. 1988 Apr;34(4):161-218
pubmed: 3282851
J Addict. 2015;2015:541536
pubmed: 25810945
Alcohol Clin Exp Res. 2017 Apr;41(4):747-757
pubmed: 28166367
J Intern Med. 2002 Jul;252(1):56-63
pubmed: 12074739
Nutr Clin Pract. 2006 Jun;21(3):245-54
pubmed: 16772542
Magnes Res. 2008 Dec;21(4):197-204
pubmed: 19271417